SNCA and Parkinson disease: Suppression of α-synuclein in CSF was greatest at the highest doses investigated: −53.6% median change from baseline on Day 15 [4500 mg (healthy participants)] and −59.0% median change from baseline on Day 85 [2000 mg (participants with Parkinson’s disease)].